Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

Age
18 years - 99 years
Gender
All
Location
1

Brief description of study

Please refer to Section 2 of the full protocol (Study Objectives). Please refer to Section 8.1 of the full protocol (Study Endpoints). Please refer to Section 8.1 of the full protocol (Study Endpoints).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: lymphoma, non-hodgkin
  • Age: 18 years - 99 years
  • Gender: All
Updated on 04 Aug 2024. Study ID: 833308
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research